Dier Mardi 4
4 · MADRIGAL PHARMACEUTICALS, INC. · Filed Mar 6, 2026
Research Summary
AI-generated summary of this filing
Madrigal (MDGL) CFO Dier Mardi Sells 1,982 Shares
What Happened
Dier Mardi, Executive Vice President and Chief Financial Officer of Madrigal Pharmaceuticals (MDGL), sold 1,982 shares in open-market transactions on March 6, 2026, generating total proceeds of approximately $853,991. On March 4, 2026, Mardi was granted 5,215 restricted stock units (RSUs) and a derivative award covering 6,519 shares (an option grant) — both reported as acquisitions (A) at $0.00. The sales were disposals (S) executed in multiple tranches at prices roughly between $425.08 and $437.65.
Key Details
- Transaction dates: Awards granted March 4, 2026; sales executed March 6, 2026; Form 4 filed March 6, 2026 (appears timely).
- Sales: 1,982 shares sold across multiple trades; prices ranged ~ $425.08–$437.65; proceeds ≈ $853,991.
- Awards: 5,215 RSUs (vest 25% each year on March 4, 2027–2030 per footnote F1); 6,519-option-type derivative with staged vesting beginning March 4, 2027 (per F12).
- Notable footnotes: Some sales were automatic to cover tax withholding on RSU vesting (F2); other sales were executed under a Rule 10b5-1 trading plan adopted Sept 2, 2025 (F3). Several reported sale prices are weighted averages covering small price ranges (F4–F11).
- Shares owned after the transactions are not included in the provided excerpt.
Context
- The March 4 entries are grants (A): RSUs and a time-based option grant that vest over multiple periods — these are compensation awards, not open-market purchases.
- The March 6 disposals include routine actions: tax-withholding sales and scheduled 10b5-1 plan trades. Such sales are common for executives and do not by themselves indicate management sentiment.
- Filing appears timely (filed March 6 for trades on March 4 and March 6); no late-filing flag reported in the provided data.
Insider Transaction Report
Form 4
Dier Mardi
EVP and CFO
Transactions
- Award
Common Stock
[F1]2026-03-04+5,215→ 14,472 total - Sale
Common Stock
[F2]2026-03-06$431.94/sh−646$279,033→ 13,826 total - Sale
Common Stock
[F3]2026-03-06$425.08/sh−40$17,003→ 13,786 total - Sale
Common Stock
[F3][F4]2026-03-06$426.86/sh−420$179,283→ 13,366 total - Sale
Common Stock
[F3][F5]2026-03-06$427.85/sh−80$34,228→ 13,286 total - Sale
Common Stock
[F3][F6]2026-03-06$429.00/sh−160$68,639→ 13,126 total - Sale
Common Stock
[F3]2026-03-06$429.58/sh−40$17,183→ 13,086 total - Sale
Common Stock
[F3][F7]2026-03-06$430.90/sh−120$51,708→ 12,966 total - Sale
Common Stock
[F3][F8]2026-03-06$432.56/sh−116$50,176→ 12,850 total - Sale
Common Stock
[F3][F9]2026-03-06$434.20/sh−160$69,472→ 12,690 total - Sale
Common Stock
[F3][F10]2026-03-06$435.31/sh−80$34,825→ 12,610 total - Sale
Common Stock
[F3][F11]2026-03-06$436.69/sh−80$34,935→ 12,530 total - Sale
Common Stock
[F3]2026-03-06$437.65/sh−40$17,506→ 12,490 total - Award
Stock Option (Right to Buy)
[F12]2026-03-04+6,519→ 6,519 totalExercise: $434.80Exp: 2036-03-04→ Common Stock (6,519 underlying)
Footnotes (12)
- [F1]Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $435.26 to $435.37, inclusive.
- [F11]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $436.46 to $436.92, inclusive.
- [F12]The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.
- [F2]This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
- [F3]These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $426.46 to $427.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $427.50 to $428.19, inclusive.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $428.51 to $429.24, inclusive.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $430.66 to $431.04, inclusive.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $432.41 to $432.99, inclusive.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $433.82 to $434.58, inclusive.
Signature
/s/ Mardi Dier|2026-03-06